In this weeks video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma next-generation sequencing (NGS) and next-generation flow (NGF).
The BOTTOM LINE: The FDA approval of the NGS test for MRD is excellent news, but this testing is still not ready for use in day-to-day clinical practice.